Q-omics provides the consensus-scored SPATA7 profile across patient tissues and cancer cell-line models. SPATA7 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPATA7 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, SPATA7 RNA expression shows 20,613 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where SPATA7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA7 survival associations across molecular data types. SPATA7 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA7 RNA expression–survival associations across cancer types. High SPATA7 expression shows unfavorable associations in ACC and CESC, but favorable associations in KIRC, BRCA, LUAD and LAML. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SPATA7 RNA expression.
This table summarizes SPATA7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SPATA7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATA7 shows lower tumor expression in THCA, LUSC, KICH, UCEC and BRCA and higher tumor expression in LIHC. The THCA box plot shows higher SPATA7 RNA expression in normal versus tumor tissue (log2 FC = −0.813, t-test p < 0.001).
This table shows molecular features associated with SPATA7 in patient tissues and cancer cell lines. In patient samples, SPATA7 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SPATA7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
